The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol Myers Squibb Foundation; CureVac; Daiichi and Pfizer; GlaxoSmithKline; JJ Innovative Medicine; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; CureVac; Daiichi and Pfizer; GlaxoSmithKline; JJ Innovative Medicine; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Takeda
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer
BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMBhigh cohort.
 
Rieke Nila Fischer
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Janssen
 
Julie George
Honoraria - MSD
Consulting or Advisory Role - DISCO Pharmaceuticals
 
Andreas H. Calaminus
No Relationships to Disclose
 
Hans Anton Schloesser
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - AstraZeneca; Tabby therapeutics
 
Jan-Phillip Weber
Honoraria - AstraZeneca; Bristol-Myers Squibb/Medarex; Daiichi Sankyo Europe GmbH; Lilly; MSD Oncology
Consulting or Advisory Role - Merck
Research Funding - Novartis; OnQ
Travel, Accommodations, Expenses - Daiichi Sankyo/Lilly; Johnson & Johnson/Janssen
 
Peter Brossart
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Research Funding - Bristol-Myers Squibb
 
Walburga Engel-Riedel
No Relationships to Disclose
 
Frank Griesinger
No Relationships to Disclose
 
Christian Grohé
No Relationships to Disclose
 
Jens Kern
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche
 
Kathrin Nachtkamp
No Relationships to Disclose
 
Jens Peter Panse
No Relationships to Disclose
 
Martin Sebastian
No Relationships to Disclose
 
Rainer Gerhard Wiewrodt
No Relationships to Disclose
 
Reinhard Büttner
No Relationships to Disclose
 
Roman K. Thomas
No Relationships to Disclose
 
Juergen Wolf
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Loxo; Loxo/Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi